Humuline 30/70 Cartridge (Insulin Human)

Humuline 30/70 Cartridge is indicated for the treatment of diabetes mellitus where a combination of rapid and intermediate insulin action is appropriate.

• Adults with type 1 diabetes who need a premixed insulin regimen.
• Adults with type 2 diabetes inadequately controlled on oral agents alone.
• Situations where a single daily injection can provide both basal and mealtime insulin coverage.
• Patients transitioning from separate regular and NPH insulin injections to a simplified delivery system.
• Use in combination with diet, exercise, and other glucose‑lowering therapies as directed by a healthcare professional.

• Humuline 30/70 delivers human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface and enhancing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, reducing endogenous glucose production. The 30 % regular insulin component acts rapidly, while the 70 % NPH component provides prolonged basal activity.

Adverse reactions to Humuline 30/70 may vary in frequency and severity, and they can affect different organ systems.

Common

• Mild hypoglycemia, especially if meals are delayed or carbohydrate intake is insufficient.
• Injection site reactions such as redness, swelling, or itching.
• Lipodystrophy, presenting as localized thickening or loss of subcutaneous fat.
• Transient weight gain associated with improved glycemic control.
• Nausea or mild gastrointestinal discomfort.
• Headache or dizziness, often related to fluctuating glucose levels.
• Localized bruising or hematoma at the injection site.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness).
• Allergic reactions ranging from urticaria to anaphylaxis.
• Persistent edema or heart failure exacerbation in susceptible individuals.
• Acute pancreatitis presenting with abdominal pain and elevated enzymes.

When prescribing or using Humuline 30/70, healthcare professionals should consider several precautionary measures to ensure safe and effective therapy.

• Assess renal and hepatic function before initiation and periodically thereafter.
• Adjust dose in patients with variable meal patterns or increased physical activity.
• Monitor for signs of hypoglycemia, especially in the elderly or those with impaired awareness.
• Use caution in pregnant or breastfeeding women; benefits must outweigh potential risks.
• Avoid using the cartridge after the expiration date or if the solution appears discolored or contains particles.
• Educate patients on proper injection technique and rotation of sites to prevent lipodystrophy.

Humuline 30/70 may interact with other medications, altering its glucose‑lowering effect or increasing the risk of adverse events.

Avoid

• Concurrent use of other rapid‑acting insulins or high‑dose insulin secretagogues that may precipitate severe hypoglycemia.
• Beta‑blockers that can mask hypoglycemia symptoms.
• Corticosteroids, which can raise blood glucose and necessitate insulin dose adjustments.

Use with caution

• Oral antidiabetic agents such as sulfonylureas or meglitinides, requiring close monitoring of blood glucose.
• Thiazide diuretics, which may increase insulin resistance.
• ACE inhibitors or ARBs, as they can affect renal function and insulin clearance.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may impair renal function and affect insulin metabolism.
• Alcohol consumption, which can cause unpredictable glucose fluctuations and potentiate hypoglycemia.